View Cigna Company Names

THE DOSE

Pharmacy Insights
and Updates from Cigna

View Cigna Company Names

THE DOSE

Pharmacy Insights
and Updates from Cigna

More News

Dedicated to making insulin more affordable and accessible – Cigna’s Patient Assurance ProgramSM

For those who live with diabetes, the costs of essential medications, like insulin, shouldn’t add to their burden. That’s why Cigna will offer the Patient Assurance Program beginning in 2020. This program will assist customers with diabetes, in participating plans, to manage their costs for eligible insulin products.

Read more

Reducing opioid use with the help of integrated dental, medical and pharmacy data

As part of a long-standing commitment to help curb opioid addiction and overdose, Cigna has collaborated with dentists to increase awareness of the dangers of opioids, the greater risk of misuse and addiction among teenagers, and safer non-opioid options to manage acute dental pain.

Read more

Customers new to opioids get safer start

Drug abuse can become ongoing and compulsive. In fact, it only takes 10 days. With just a 10-day prescription, one in five people have an increased risk of opioid addiction.1 The Cigna Safe Opioid Starts (SOS) program attempts to help prevent this tough situation from taking root.

  1. Centers for Disease Control and Prevention. “Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States 2006–2015.” March 17, 2017. <https://www.cdc.gov/mmwr/volumes/66/wr/mm6610a1.htm>

Read more

Lyrica loses patent protection, generics now available

Lyrica is commonly used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, fibromyalgia or spinal cord injury. It is also used with other medications to treat certain types of seizures.2

  1. Lyrica. WebMD.com. August 5, 2019. https://www.webmd.com/drugs/2/drug-93965/lyrica-oral/details

Read more

New treatment for infants with spinal muscular atrophy

On May 24, 2019, the U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec), a new gene replacement therapy. Zolgensma is approved to treat children less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene, a leading genetic cause of infant mortality.3

  1. Zolgensma Prescribing Information. May 2019. <https://www.avexis.com/content/pdf/prescribing_information.pdf.>

Read more

Drug Updates

Cigna Pharmacy Management®

As a Pharmacy Benefits Manager within a global health service company, we uniquely deliver personalized solutions that support the whole person. Through integrated capabilities, we address every aspect of our customers’ wellness, including physical and emotional health. Our goal is to deliver greater value to you and your employees, helping them improve their well-being while you control your costs.

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require you to use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, contact a Cigna representative. Group medical and pharmacy plans are insured and/or administered by Cigna Health and Life Insurance Company or its affiliates. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. All pictures are used for illustrative purposes only. This website is not intended for residents of New Mexico.

© 2019 Cigna. All rights reserved